Document Detail


Growth inhibition and differentiation of C6 glioma cells on treatment with hmba.
MedLine Citation:
PMID:  11448101     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
HMBA, a differentiation inducer belonging to the class of hybrid polar compounds, is known to induce terminal differentiation of a number of leukemic and solid tumour cell lines. In this report we have shown that HMBA markedly inhibits growth of C6 glioma cells at non-cytotoxic concentrations ranging from 2.5 m m to 10 m m in a dose-dependent manner. The growth inhibitory effect can be detected as early as 18--24 h. By the sixth day the growth inhibition decreases at all the concentrations tested. Treatment with HMBA results in an accumulation of C6 cells in G0/G1 phase along with a decrease in the number of cells in S phase. HMBA induces morphological differentiation of C6 cells and increases expression of glial fibriliary acidic protein (GFAP), a marker for mature astrocytes. HMBA induces c-fos and represses cycloheximide-induced c-jun and fra-1 expression. HMBA-induced growth inhibition of C6 cells is accompanied by a decrease in Cdk4 protein levels. However, HMBA fails to sustain low Cdk4 levels, which may be responsible for HMBA's failure to sustain the growth inhibitory effect.
Authors:
N V Shirsat; J J Kayal; S Shaikh; A Mehta
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cell biology international     Volume:  25     ISSN:  1065-6995     ISO Abbreviation:  Cell Biol. Int.     Publication Date:  2001  
Date Detail:
Created Date:  2001-07-12     Completed Date:  2001-10-04     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9307129     Medline TA:  Cell Biol Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  621-7     Citation Subset:  IM    
Copyright Information:
Copyright 2001 Academic Press.
Affiliation:
Neuro-Oncology Division, Cancer Research Institute, Tata Memorial Centre, Parel, Mumbai-400012, India. cri3@soochak.ncst.ernet.in
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetamides / pharmacology*
Antineoplastic Agents / pharmacology*
Brain Neoplasms / drug therapy*,  metabolism,  pathology
Cell Cycle
Cell Differentiation / drug effects
Cell Division / drug effects
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinases / metabolism
DNA, Neoplasm / analysis
Drug Screening Assays, Antitumor
Glioma / drug therapy*,  metabolism,  pathology
Proto-Oncogene Proteins*
Proto-Oncogene Proteins c-fos / metabolism
Proto-Oncogene Proteins c-jun / metabolism
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Acetamides; 0/Antineoplastic Agents; 0/DNA, Neoplasm; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-fos; 0/Proto-Oncogene Proteins c-jun; 0/fos-related antigen 1; 3073-59-4/hexamethylene bisacetamide; EC 2.7.11.22/Cyclin-Dependent Kinase 4; EC 2.7.11.22/Cyclin-Dependent Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cytostatic effect of inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CD...
Next Document:  Cloning, sequencing and expression of a cDNA encoding the mouse L35a ribosomal protein during differ...